Differentiation of mouse bone marrow derived stem cells toward microglia-like cells
© Hinze and Stolzing; licensee BioMed Central Ltd. 2011
Received: 17 February 2011
Accepted: 19 August 2011
Published: 19 August 2011
Microglia, the macrophages of the brain, have been implicated in the causes of neurodegenerative diseases and display a loss of function during aging. Throughout life, microglia are replenished by limited proliferation of resident microglial cells. Replenishment by bone marrow-derived progenitor cells is still under debate. In this context, we investigated the differentiation of mouse microglia from bone marrow (BM) stem cells. Furthermore, we looked at the effects of FMS-like tyrosine kinase 3 ligand (Flt3L), astrocyte-conditioned medium (ACM) and GM-CSF on the differentiation to microglia-like cells.
We assessed in vitro- derived microglia differentiation by marker expression (CD11b/CD45, F4/80), but also for the first time for functional performance (phagocytosis, oxidative burst) and in situ migration into living brain tissue. Integration, survival and migration were assessed in organotypic brain slices.
The cells differentiated from mouse BM show function, markers and morphology of primary microglia and migrate into living brain tissue. Flt3L displays a negative effect on differentiation while GM-CSF enhances differentiation.
We conclude that in vitro- derived microglia are the phenotypic and functional equivalents to primary microglia and could be used in cell therapy.
Keywordsbone marrow stem cells microglia Flt3L GM-CSF neurodegeneration differentiation
Microglias constitute about 10% of the cell population of the brain and represent the most important first immune defense of the CNS. They are phagocytic, cytotoxic, antigen-presenting cells which promote brain tissue repair after injury . Primary microglia differ from other blood macrophages in the expression levels of markers like CD11b/CD45low/high , CD68 low/high  and substance P levels . Because of the overlap in markers there is an ongoing discussion about the distinction between dendritic cells, macrophages and microglia. The regulation of marker levels and activity has led to the proposition that microglia could be immature or resting macrophages . However, there is a lack of correlation between marker expression and actual functional capacity, which is the most important hallmark for therapeutic use. Microglia in the brain normally display a quiescent state in which phagocytosis, immune response and migration are down-regulated and the microglia show a ramified morphology with long processes . Microglia react to inflammation by switching to an activated state and taking on an amoeboid morphology . They migrate towards sites of injury and lesion and extracellular debris such as amyloid-β plaques . An important function of microglia is the "oxidative burst" - a sudden spike in reactive oxygen species (ROS) levels generated by the stimulation of the NADPH oxidase. This ROS production is accompanied by the release of other factors, including lysosomal proteases. This mechanism, often interpreted as a 'defense' response that can protect the brain from pathogens, is a characteristic feature of microglia [9, 10]. Microglia are thought to originate from the yolk sac during embryogenesis  and are replenished by local proliferation throughout adult life. The supplementation by progenitor cells from the bone marrow is controversial [1, 11, 12]. Bone marrow-derived microglia can be observed in the brain after systemic transplantation . While BM chimeras have shown BM-derived microglia , other findings indicate that without irradiation no invasion is observable in the time frame of 1-2 months [15, 16]. But also in transplantations without irradiation intravenously injected hematopoietic stem cells have been observed to migrate to the brain, differentiate into microglia and reduce infarct size . The maturation of progenitors to microglia occurs under the influence of factors secreted by astrocytes . Both local and peripheral replenishment do not seem to suffice to prevent the slow deterioration of the microglia cell population and function with age [19, 20]. In human Alzheimer patients microglia associated with tau tangles were found to be dystrophic, which might precede neurodegeneration . In old rats there have been indications that the proliferation of microglia after injury is stronger than in young rats . In vitro, proliferating rat microglia have been reported to undergo telomere shortening  and aged microglia of several species have been observed to loose their ability to perform normal microglia functions [19, 20, 24–28]. These findings support the hypothesis of a slow deterioration of microglia as a contribution to the onset of neurodegeneration [20, 21].
The maturation of progenitors to microglia occurs under the influence of factors secreted by astrocytes . Both local and peripheral replenishment do not seem to suffice to prevent the slow deterioration of microglia cell population and function with age [17, 18]. The resident microglia are suspected to reach replicative senescence during aging . Microglia have been differentiated in vitro from peripheral blood monocytes [4, 18] and from embryonic stem cells . In this context, we focus on differentiating microglia from bone marrow. This approach was first demonstrated by Servet-Delprat et al. , who obtained 20% cells with microglia-like morphology and marker expression (CD115+, CD11b+, F4/80+, CD80 low, CD86-) after culturing mouse BM cells in Flt3L for 11 days and then mixing the cell-containing supernatant with astrocyte-conditioned medium for 6 days. However, since the use of Flt3L was not controlled in that protocol, its role as a factor in microglia differentiation remained unclear. Davoust et al.  used a similar protocol but significantly shorter culture times and no Flt3L to obtain CD11b +, CD45 +, MHCII -, B220 low, CD34+, and CD86 low cells from mouse BM (the percentage yield is not reported). The success of microglial cell differentiation has been mostly judged by measurement of the expression of markers and the morphology of the differentiated cells. It remained unclear to what extent in vitro- derived microglia-like cells share the functional capacities of original microglia. To address this question, we followed the protocol of Servet-Delprat et al.  (with and without Flt3L), measured phagocytosis and oxidative burst as hallmarks of microglial function and tested the ability to survive and migrate in brain tissue.
Surface marker expression
Untreated bone marrow cells showed significantly increased CD11b/CD45 expression after 17 days in culture. The same was observed in cultures treated with ACM/GM-CSF. Non-adherent BM cells treated with ACM/GM-CSF and whole bone marrow and cultivated for 17 days are observed in the same region as primary microglia in the flow cytometry plots. Flt3L has an adverse effect on differentiation, leading to low levels of CD11b/CD45-positive cells in all Flt3L-supplemented samples.
Flow cytometric analysis of the cells differentiated and analyzed for microglia specific markers
Cells in microglia gate
BM 0 days
BM 7 days
BM 10 days
BM 17 days
Sup. BM day 11
Sup. BM day 11
Time course of marker expression
Phagocytic activity and oxidative burst
Migration in organotypic brain slices
We investigated the differentiation and function of microglia from bone marrow (BM) stem cells using ACM and GM-CSF with and without Flt3L. As opposed to M-CSF used by Davoust et al. , we used GM-CSF as this is reported to expand primary microglia more successfully than M-CSF [32, 33]. Primary microglia have been characterized as CD11b+/CD45low and distinguished from primary macrophages on the basis of their CD45 expression level . The in vitro- differentiated microglia derived in this manner generally show marker expression levels similar to those of primary microglia. It is known that ACM treatment of BM cells can produce cells with markers for microglia . However, such cells have not been further characterized with respect to phagocytic capacity and migration behavior inside the brain or tested for the microglia-typical oxidative burst. Here we demonstrate that BMC cultured in the presence of ACM and GM-CSF show phagocytosis and oxidative burst activity typical of microglia. The cells also had long and branched processes similar to primary microglia. Flt3L supplementation diminished the functional markers and microglia-like morphology. Thus, among the parameters tested here, the 'optimal' protocol for in vitro differentiation of microglia relies on ACM, GM-CSF without Flt3L. Interestingly, we find that even unsupplemented BM contains a subpopulation positive for microglial markers (CD11b/CD45, F4/80) and that this population is more dominant after 17 days of differentiation. However, we find that microglia-like cells derived from BM without any supplementation display only low phagocytosis and oxidative burst levels compared to ACM/GM-CSF-supplemented cells. Generally, unsupplemented bone marrow cultures show mixed cell morphologies whereas supplemented cultures are prone to display more homogeneous, branched cell types. Flt3L has been used for the sequential differentiation of BM cells presumably because it improves hematopoietic stem cell (HSC) survival in vitro  and in vivo . Servet-Delprat et al. only investigated Flt3L-supplemented cells and did not consider unsupplemented cells. The group estimated 20% microglia from the number of ramified cells, which is confirmed by our results for ACM, GM-CSF, Flt3L-supplemented cells. However, much higher functional microglia 'yield' can be obtained in the absence of Flt3L. In fact, we demonstrate that supplementation with Flt3L diminishes microglia differentiation: where Flt3L is added alone or in combination with ACM, GM-CSF, the number of cells showing microglial markers as well as the capacity for brain migration, phagocytosis and oxidative burst decreases. The differentiation protocols investigated here rely on using the supernatant at day 11 to select for non-adherent HSC and then culturing it in the presence of ACM for another 6 days. The tactic here is to first obtain a relatively pure HSC population which then partially differentiates into adherent microglia. Flt3L has been shown to expand HSC and transiently increase adhesion of HSC in culture and it might play a role in mobilization of HSC into the blood stream . Therefore, the amount of microglia progenitor cells in the day 11 supernatant bone marrow culture might be decreased or the differentiation might be delayed. In addition, Flt3L combined with GM-CSF has been shown to enhance dendritic cell differentiation . This fact is supported by work with Flt3L knockout mice where levels of dendritic cells are increased and numbers of myeloid cells, the progenitors of microglia, are decreased . These factors may explain why Flt3L supplementation yields a lower count in functional in vitro-derived microglia.
The microglial cell population is known to be heterogeneous and to overlap with dendritic cell-like populations in the brain . The various procedures employed for microglial differentiation might result in distinct subpopulations or activation states. The choice of the protocol might have a substantial impact on the effect transplanted cells will have in vivo. This is especially important because different subsets of microglia have been linked to tolerance induction or immune reaction .
In co-cultures with organotypic brain slices the microglia-like cells survived and proliferated for at least 10 days. It is known that the majority of primary microglia or BV2 cells only migrate over the surface layer of brain tissues under non-inflammatory conditions [40, 41] while a subpopulation migrates into the tissue. Directed migration towards sites of injury induced by NMDA on the surface of brain slice cultures has been observed for primary microglia . The damaged surface of the brain slice cultures even attracts slice-internal microglia, which showed directed migration to the surface . This is supported by our results: Most cells migrate into the brain slice tissue superficially while in vitro- derived (ACM/GM-CSF, but without Flt3L) microglia migrated deepest into the tissue and showed both amoeboid and rounded morphologies suggesting an activated state.
The microglial cell population is known to overlap with dendritic cell-like populations in the brain . Dendritic cells differentiate from monocytes and mature by exposure to antigens or under inflammatory conditions . There is evidence that cells showing an immature dendritic phenotype can differentiate from microglia under the influence of GM-CSF . At the same time, dendritic cells can be differentiated to microglia-like cells which inhibit T cell proliferation induced by mature dendritic cells . In the current study, microglia were differentiated using ACM and GM-CSF. There is evidence that cells showing an immature dendritic phenotype can differentiate from microglia under the influence of GM-CSF . At the same time, dendritic cells can be differentiated to microglia like cells which inhibit T cell proliferation induced by mature dendritic cells . Dendritic cells can act both tolerogenic and immunogenic, depending on their maturation state . CD11c-positive microglia have been observed to acquire immature dendritic cell phenotypes in models of acute experimental autoimmune encephalomyelitis (EAE) and to be part of the antigen-presenting cells responsible for the disease . The risk in using in vitro- differentiated microglia in a therapy is that these cell populations might contain a dendritic cell-like subpopulation expressing CD11c, which can stimulate an autoimmune inflammation within the CNS . This might lead to the development of an autoimmune phenotype.
It was one of our reasons for performing a functional analysis on our in vitro- differentiated microglia that it was described in the literature that the microglial subpopulations displaying similarities to dendritic cells and expressing CD11c (and other dendritic markers) do not contain any phagocytic vacuoles . Our cells are selected for a highly phagocytic activity. This is an additional feature required to potentially clear protein aggregates like amyloid plaques from the brain parenchyma, but would also avoid the transplantation of autoimmune-inducing microglia. A risk still persists, as it was shown that CD11b-positive microglia can produce cells with dendritic features which can acquire the antigen-presenting activities after activation . However, dendritic cells can act both immunogenic and tolerogenic, depending on their maturation state . This could be beneficial for reducing transplant rejection  or used to treat autoimmune inflammation, for example in acute experimental autoimmune encephalomyelitis [5, 45]. Transplantation of human microglia in ischemic brains modulates inflammation and reduces neuronal apoptosis . Microglia provide neuroprotection in hippocampal slice cultures while lipopolysaccharide-stimulated microglia do not . The various procedures employed for microglial differentiation might result in distinct activation or differentiation states. The choice of the protocol and the composition of the cells might have a substantial impact on the effect transplanted cells will have in vivo.
The in vitro- differentiated cells correspond to primary microglia in phenotype and function. The importance of microglia in degenerative diseases makes them an interesting target for therapeutic approaches. If neurodegenerative diseases occur in part due to the age-dependent deterioration of the microglial cell population number and/or function, functional microglia supplementation could have beneficial effects. For example, injection of primary microglia into the brain of rats led to an increased amyloid beta clearance . Furthermore, the suspected ability of microglial precursors to cross the blood-brain barrier and to seek out sites of neuroinflammation renders them potentially useful drug delivery vehicles . In vitro- derived microglia will need to demonstrate the functional capacity of 'real' microglial cells and our research makes some contributions to this aim. However, extensive further tests will be required before such cells are deemed suitable and safe for transplantation.
C57BL/6 mice from the MEZ of the University of Leipzig and Charles River (Sulzfeld, Germany) were used as sources for bone marrow, primary microglia and organotypic brain slices in accordance with local animal ethics permissions.
Isolation of bone marrow and cell culture
Bone marrow was obtained by centrifugation of femora and tibiae. Isolated bone marrow cells were cultured at a density of 107 cells in a 60 mm petri dish in 5 ml of Dulbecco's minimal essential medium (DMEM)/low glucose (Hyclone Laboratories Inc.), supplemented with 10% fetal calf serum (FCS -Invitrogen) and 100 units/ml Penicillin, 100 μg/ml Streptomycin.
Astrocyte-conditioned medium was produced by incubating medium (DMEM/10% FCS) for 24 h with primary mouse astrocyte cultures .
Isolation of primary microglia
Primary microglia were isolated from brains of 1-3 day old mice. The meninges was removed and the whole brain was titrated in DMEM/10% FCS and Pen/Strep. The resulting cell and tissue suspension of 3 brains was cultured in a poly L-lysine-coated culture flask. After 24 h, the supernatant was removed from the cell culture and new medium was added. After 7 days, 50% of the culture medium was changed. At 14 days, microglia were removed by gentle shaking .
Differentiation towards microglia-like cells
Experiment set 1
Whole bone marrow (107 cells) was cultivated over the time periods of 7, 10 and 17 days in 10 ml DMEM/10% FCS in a 60 mm petri dish and analyzed for certain cell surface markers at these time points. When cells were cultured for longer than 10 days, 50% of medium was replaced at day 10.
Experiment set 2
Whole bone marrow (107 cells) was cultured for 11 days in a 90 mm petri dish in either plain DMEM/10% FCS or DMEM/10% FCS supplemented with 5 ng/ml Flt3L (noFlt3L and Flt3L groups, respectively). After 11 days, cells of both groups (with and without Flt3L) were analyzed for surface markers and non-adherent cells were further cultured for a period of 6 days. To this end, cells from 2 petri dishes were aspirated, transferred to a new 60 mm petri dish and cultured in DMEM/10% FCS supplemented with 50% ACM and 20 ng/ml GM-CSF (noFlt3L and Flt3L + suppl., groups); or supplements were omitted for Flt3L group (Flt3L - suppl. group).
The differentiated cells were tested for the surface markers F4/80, CD11b, CD45 and CD11b/CD45 double expression. The cells were trypsinized, centrifuged at 300 g for 5 min and fixed in 4% paraformaldehyde. They were washed with phosphate buffered saline (PBS). Afterwards, cells were incubated for 2 h at 4°C with CD11b (1:250) or F4/80 (1:250) antibody (both Alexa 488-labeled, eBioscience) or with CD45 (1:100) antibody (PE-labeled, eBioscience). The incubated cells were washed again and fluorescence was measured with a Beckmann Coulter FC 500.
Phagocytic activity of the differentiated cells was measured by the uptake of fluorescent beads (Sigma, 2 μm yellow/green fluorescent). In a first step, samples of 3*105 cells were activated with phorbol-12-myristate-13-acetate (PMA) (0.1 μM) for 15 min at 37°C . Afterwards they were incubated in 50 μl DMEM/10% FCS together with 50 μl opsonized (FCS) beads for 48 h at 37°C, 5% CO2. The uptake of fluorescent beads was observed qualitatively in a Zeiss Axio Observer fluorescence microscope. For quantitative assessment the cells were trypsinized and resuspended in PBS (Invitrogen). Cells were repeatedly washed and fluorescence was measured in a Beckmann Coulter FC 500.
Nitro Blue Tetrazolium (NBT)
104 cells were seeded on cover slips. They were incubated with 30 μl 1 mg/ml NBT and 100 nM PMA for 45 min at 37°C and 5% CO2 . Light microscope pictures were taken with a Leica DM IL (Leica) using the LAZ EZ 1.4.0 software (Leica). Pictures were brightness- and contrast-adjusted with GIMP 2.4.5 and Power Point (Microsoft).
Dihydrorhodamine 123 (DHR123)
3*105 Cells were incubated in PBS for 15 min at 37°C with 0.1 μM PMA. Controls were incubated without PMA. Afterwards, 50 μM DHR123 (Invitrogen) was added and the cells were incubated for additional 15 min at 37°C. The cells were fixed with 4% PFA and fluorescence was measured in a Beckmann Coulter FC 500.
A DM IL (Leica) and the LAZ EZ 1.4.0 software (Leica) were used to take light microscopic pictures.
Brain slice cultures
2-3 month old C57BL/6 mice were killed by cervical dislocation. The brain was isolated and cut into 350 μm slices in cold preparation medium (HBSS and 10% FCS (Invitrogen) using a Leica VT 1000 S vibratome). The slices were transferred to an insert (Millicell CM 0.4 μm, Millipore) and cultivated with brain slice culture medium (50% DMEM/high glucose (HyClone Laboratories Inc.), 25% Horse Serum (Invitrogen), 25% HBSS (Invitrogen), 1 μg/ml insulin, 100 units/ml penicillin, 100 μg/ml streptomycin). Medium was changed every 2-3 days. The brain slices were cultured for 9 days before cells were seeded on them .
Survival and migration in brain slice cultures
Differentiated cells were labeled with DIO (Invitrogen) for 20 min. They were added on top of the brain slices. The viability of brain slice cultures was checked by performing PI staining. The survival of seeded cells was checked by adding 5 μg/ml propidium iodide to the medium, washing and scanning the slices with a confocal microscope TCS SP2 (Leica Microsystems) using the accompanying software LCS 2.6 (Leica Microsystems). The slices were scanned to a depth of 160 μm after 10 days of co-culture. Images were contrast- and brightness-adjusted with GIMP 2.4.5 and Power Point (Microsoft).
All data are presented as means ± SE. Statistic analysis were made using SigmaPlot 10.0/SigmaStat 3.5 software (SYSTAT, Erkrath, Germany).
We are grateful for support concerning confocal microscopy by Prof. Dr. Käs and Undine
Dietrich, Biophysics Group University Leipzig and for support concerning brain slice cultures
by Prof. Dr. Seeger and Gabriele Lindner, Veterinary Anatomy University Leipzig. We thank Dr. Sethe for help in the preparation of the manuscript.
- Simard AR, Rivest S: Neuroprotective effects of resident microglia following acute brain injury. J Comp Neurol. 2007, 504 (6): 716-729. 10.1002/cne.21469.View ArticlePubMedGoogle Scholar
- Ford AL, Goodsall AL, Hickey WF, Sedgwick JD: Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol. 1995, 154 (9): 4309-4321.PubMedGoogle Scholar
- Slepko N, Levi G: Progressive activation of adult microglial cells in vitro. Glia. 1996, 16 (3): 241-246. 10.1002/(SICI)1098-1136(199603)16:3<241::AID-GLIA6>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G: Characterization of human monocyte-derived microglia-like cells. Glia. 2006, 54 (3): 183-192. 10.1002/glia.20372.View ArticlePubMedGoogle Scholar
- Almolda B, Gonzalez B, Castellano B: Activated microglial cells acquire an immature dendritic cell phenotype and may terminate the immune response in an acute model of EAE. J Neuroimmunol. 2010, 223 (12): 39-54.View ArticlePubMedGoogle Scholar
- Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19 (8): 312-318. 10.1016/0166-2236(96)10049-7.View ArticlePubMedGoogle Scholar
- Stence N, Waite M, Dailey ME: Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia. 2001, 33 (3): 256-266. 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008, 451 (7179): 720-724. 10.1038/nature06616.PubMed CentralView ArticlePubMedGoogle Scholar
- McGeer PL, McGeer EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995, 21 (2): 195-218.View ArticlePubMedGoogle Scholar
- Stolzing A, Sethe S, Grune T: Chronically active: activation of microglial proteolysis in ageing and neurodegeneration. Redox Rep. 2005, 10 (4): 207-213. 10.1179/135100005X70198.View ArticlePubMedGoogle Scholar
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER: Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010, 330 (6005): 841-845. 10.1126/science.1194637.PubMed CentralView ArticlePubMedGoogle Scholar
- Lawson LJ, Perry VH, Gordon S: Turnover of resident microglia in the normal adult mouse brain. Neuroscience. 1992, 48 (2): 405-415. 10.1016/0306-4522(92)90500-2.View ArticlePubMedGoogle Scholar
- Rodriguez M, Alvarez-Erviti L, Blesa FJ, Rodriguez-Oroz MC, Arina A, Melero I, Ramos LI, Obeso JA: Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis. 2007, 28 (3): 316-325. 10.1016/j.nbd.2007.07.024.View ArticlePubMedGoogle Scholar
- Dobrenis K: Microglia in cell culture and in transplantation therapy for central nervous system disease. Methods. 1998, 16 (3): 320-344. 10.1006/meth.1998.0688.View ArticlePubMedGoogle Scholar
- Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM: Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007, 10 (12): 1538-1543. 10.1038/nn2014.View ArticlePubMedGoogle Scholar
- Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M: Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007, 10 (12): 1544-1553. 10.1038/nn2015.View ArticlePubMedGoogle Scholar
- Schwarting S, Litwak S, Hao W, Bahr M, Weise J, Neumann H: Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke. 2008, 39 (10): 2867-2875. 10.1161/STROKEAHA.108.513978.View ArticlePubMedGoogle Scholar
- Sievers J, Parwaresch R, Wottge HU: Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: morphology. Glia. 1994, 12 (4): 245-258. 10.1002/glia.440120402.View ArticlePubMedGoogle Scholar
- Stolzing A, Widmer R, Jung T, Voss P, Grune T: Tocopherol-mediated modulation of age-related changes in microglial cells: turnover of extracellular oxidized protein material. Free Radic Biol Med. 2006, 40 (12): 2126-2135. 10.1016/j.freeradbiomed.2006.02.011.View ArticlePubMedGoogle Scholar
- Streit WJ: Microglial senescence: does the brain's immune system have an expiration date?. Trends Neurosci. 2006, 29 (9): 506-510. 10.1016/j.tins.2006.07.001.View ArticlePubMedGoogle Scholar
- Streit WJ, Braak H, Xue QS, Bechmann I: Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118 (4): 475-485. 10.1007/s00401-009-0556-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Conde JR, Streit WJ: Effect of aging on the microglial response to peripheral nerve injury. Neurobiol Aging. 2006, 27 (10): 1451-1461. 10.1016/j.neurobiolaging.2005.07.012.View ArticlePubMedGoogle Scholar
- Flanary BE, Streit WJ: Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia. 2004, 45 (1): 75-88. 10.1002/glia.10301.View ArticlePubMedGoogle Scholar
- Zhao C, Li WW, Franklin RJ: Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging. 2006, 27 (9): 1298-1307. 10.1016/j.neurobiolaging.2005.06.008.View ArticlePubMedGoogle Scholar
- Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ: Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res. 2007, 10 (1): 61-74. 10.1089/rej.2006.9096.View ArticlePubMedGoogle Scholar
- Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K: Microglia derived from aging mice exhibit an altered inflammatory profile. Glia. 2007, 55 (4): 412-424. 10.1002/glia.20468.View ArticlePubMedGoogle Scholar
- Sawada M, Sawada H, Nagatsu T: Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases. Neurodegener Dis. 2008, 5 (3-4): 254-256. 10.1159/000113717.View ArticlePubMedGoogle Scholar
- Neumann H, Kotter MR, Franklin RJ: Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009, 132 (Pt 2): 288-295.PubMed CentralPubMedGoogle Scholar
- Tsuchiya T, Park KC, Toyonaga S, Yamada SM, Nakabayashi H, Nakai E, Ikawa N, Furuya M, Tominaga A, Shimizu K: Characterization of microglia induced from mouse embryonic stem cells and their migration into the brain parenchyma. J Neuroimmunol. 2005, 160 (1-2): 210-218. 10.1016/j.jneuroim.2004.10.025.View ArticlePubMedGoogle Scholar
- Servet-Delprat C, Arnaud S, Jurdic P, Nataf S, Grasset MF, Soulas C, Domenget C, Destaing O, Rivollier A, Perret M: Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol. 2002, 3: 15-10.1186/1471-2172-3-15.PubMed CentralView ArticlePubMedGoogle Scholar
- Davoust N, Vuaillat C, Cavillon G, Domenget C, Hatterer E, Bernard A, Dumontel C, Jurdic P, Malcus C, Confavreux C: Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia. Faseb J. 2006, 20 (12): 2081-2092. 10.1096/fj.05-5593com.View ArticlePubMedGoogle Scholar
- Lee SC, Liu W, Brosnan CF, Dickson DW: GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia. 1994, 12 (4): 309-318. 10.1002/glia.440120407.View ArticlePubMedGoogle Scholar
- Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Stern LJ, Strominger JL, Riese R: Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA. 2001, 98 (11): 6295-6300. 10.1073/pnas.111152498.PubMed CentralView ArticlePubMedGoogle Scholar
- Wodnar-Filipowicz A: Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci. 2003, 18: 247-251.PubMedGoogle Scholar
- Solanilla A, Grosset C, Duchez P, Legembre P, Pitard V, Dupouy M, Belloc F, Viallard JF, Reiffers J, Boiron JM: Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. Br J Haematol. 2003, 120 (5): 782-786. 10.1046/j.1365-2141.2003.04155.x.View ArticlePubMedGoogle Scholar
- Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996, 184 (5): 1953-1962. 10.1084/jem.184.5.1953.View ArticlePubMedGoogle Scholar
- McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000, 95 (11): 3489-3497.PubMedGoogle Scholar
- Fischer HG, Reichmann G: Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol. 2001, 166 (4): 2717-2726.View ArticlePubMedGoogle Scholar
- Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, Stalder AK, Staufenbiel M, Neumann H, Carson MJ: Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro. 2010, 2 (3): e00037-PubMed CentralView ArticlePubMedGoogle Scholar
- Hailer NP, Jarhult JD, Nitsch R: Resting microglial cells in vitro: analysis of morphology and adhesion molecule expression in organotypic hippocampal slice cultures. Glia. 1996, 18 (4): 319-331. 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Heppner FL, Skutella T, Hailer NP, Haas D, Nitsch R: Activated microglial cells migrate towards sites of excitotoxic neuronal injury inside organotypic hippocampal slice cultures. Eur J Neurosci. 1998, 10 (10): 3284-3290. 10.1046/j.1460-9568.1998.00379.x.View ArticlePubMedGoogle Scholar
- Bai B, Song W, Ji Y, Liu X, Tian L, Wang C, Chen D, Zhang X, Zhang M: Microglia and microglia-like cell differentiated from DC inhibit CD4 T cell proliferation. PLoS One. 2009, 4 (11): e7869-10.1371/journal.pone.0007869.PubMed CentralView ArticlePubMedGoogle Scholar
- Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol. 2003, 21: 685-711. 10.1146/annurev.immunol.21.120601.141040.View ArticlePubMedGoogle Scholar
- Prodinger C, Bunse J, Kruger M, Schiefenhovel F, Brandt C, Laman JD, Greter M, Immig K, Heppner F, Becher B: CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol. 2011, 121 (4): 445-458. 10.1007/s00401-010-0774-y.View ArticlePubMedGoogle Scholar
- Magnus T, Chan A, Grauer O, Toyka KV, Gold R: Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol. 2001, 167 (9): 5004-5010.View ArticlePubMedGoogle Scholar
- Narantuya D, Nagai A, Sheikh AM, Wakabayashi K, Shiota Y, Watanabe T, Masuda J, Kobayashi S, Kim SU, Yamaguchi S: Microglia transplantation attenuates white matter injury in rat chronic ischemia model via matrix metalloproteinase-2 inhibition. Brain Res. 2010, 1316: 145-152.View ArticlePubMedGoogle Scholar
- Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, Dinkel K: Microglia provide neuroprotection after ischemia. Faseb J. 2006, 20 (6): 714-716.PubMedGoogle Scholar
- Takata K, Kitamura Y, Yanagisawa D, Morikawa S, Morita M, Inubushi T, Tsuchiya D, Chishiro S, Saeki M, Taniguchi T: Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett. 2007, 581 (3): 475-478. 10.1016/j.febslet.2007.01.009.View ArticlePubMedGoogle Scholar
- Schloendorn J, Sethe S, Stolzing A: Cellular therapy using microglial cells. Rejuvenation Res. 2007, 10 (1): 87-99. 10.1089/rej.2006.0511.View ArticlePubMedGoogle Scholar
- Floden AM, Combs CK: Microglia repetitively isolated from in vitro mixed glial cultures retain their initial phenotype. J Neurosci Methods. 2007, 164 (2): 218-224. 10.1016/j.jneumeth.2007.04.018.View ArticlePubMedGoogle Scholar
- Chan HT, Kedzierska K, O'Mullane J, Crowe SM, Jaworowski A: Quantifying complement-mediated phagocytosis by human monocyte-derived macrophages. Immunol Cell Biol. 2001, 79 (5): 429-435. 10.1046/j.1440-1711.2001.01027.x.View ArticlePubMedGoogle Scholar
- Yu WH, Go L, Guinn BA, Fraser PE, Westaway D, McLaurin J: Phenotypic and functional changes in glial cells as a function of age. Neurobiol Aging. 2002, 23 (1): 105-115. 10.1016/S0197-4580(01)00258-5.View ArticlePubMedGoogle Scholar
- Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991, 37 (2): 173-182. 10.1016/0165-0270(91)90128-M.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.